In the article by Kubitza et al. [1] there was an error in the final paragraph on p 95.
The first two sentences were printed as follows:
As expected, no relevant differences in PT prolongation were observed between healthy subjects and subjects with mild renal impairment at baseline and after administration of rivaroxaban. By contrast, a significant increase in PT prolongation was detected in subjects with moderate renal impairment, compared with healthy subjects.
This should have read:
As expected, no relevant differences in PT prolongation were observed between healthy subjects and subjects with mild hepatic impairment at baseline and after administration of rivaroxaban. By contrast, a significant increase in PT prolongation was detected in subjects with moderate hepatic impairment, compared with healthy subjects.
The authors apologise for this error.
Reference
- Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76:89–98. doi: 10.1111/bcp.12054. [DOI] [PMC free article] [PubMed] [Google Scholar]